Compass Therapeutics, Inc. (NASDAQ:CMPX) Stock Has Average Target Price of $10.21

Compass Therapeutics, Inc. (NASDAQ:CMPX) has received a consensus recommendation of “Moderate Buy” from the seventeen research firms that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, twelve have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $10.25.

Several research firms have commented on CMPX. Wedbush set a $4.00 price objective on Compass Therapeutics in a research note on Wednesday, September 23rd. Citizens Jmp decreased their target price on Compass Therapeutics to $4.00 and set a “market outperform” rating on the stock in a research report on Wednesday, September 23rd. LADENBURG THALM/SH SH started coverage on Compass Therapeutics in a research note on Wednesday, July 1st. They issued a “buy” rating and a $5.00 price target on the stock. Piper Sandler boosted their price target on Compass Therapeutics from $4.00 to $6.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. Finally, Guggenheim reduced their price objective on Compass Therapeutics to $4.00 and set a “buy” rating for the company in a research note on Wednesday, September 23rd.

Compass Therapeutics Stock Up 3.9%

CMPX stock opened at $1.00 on Friday. The stock has a market capitalization of $179.75 million, a P/E ratio of -2.50 and a beta of 1.02. The firm has a 50-day simple moving average of $1.94 and a 200-day simple moving average of $2.65. Compass Therapeutics has a 52 week low of $0.83 and a 52 week high of $6.88.

Compass Therapeutics (NASDAQ:CMPX) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.02). On average, analysts expect that Compass Therapeutics will post -0.47 earnings per share for the current year.

Institutional Investors Weigh In On Compass Therapeutics

Hedge funds have recently modified their holdings of the business. Parallel Advisors LLC acquired a new position in Compass Therapeutics during the first quarter worth about $28,000. PNC Financial Services Group Inc. raised its holdings in Compass Therapeutics by 2,572.6% in the 1st quarter. PNC Financial Services Group Inc. now owns 11,038 shares of the company’s stock valued at $58,000 after acquiring an additional 10,625 shares during the last quarter. HB Wealth Management LLC acquired a new stake in Compass Therapeutics in the 2nd quarter valued at about $29,000. State of Wyoming purchased a new position in Compass Therapeutics in the 2nd quarter worth approximately $31,000. Finally, Pictet Asset Management Holding SA purchased a new position in Compass Therapeutics in the 1st quarter worth approximately $76,000. 68.43% of the stock is currently owned by institutional investors and hedge funds.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc is a clinical-stage biotechnology company focused on developing antibody-based immunotherapies for the treatment of cancer. The company’s research is centered on therapies designed to activate and direct the immune system against tumor cells, with the goal of improving anti-tumor responses and addressing limitations associated with existing cancer treatments.

Compass Therapeutics’ pipeline has included CTX-471, an investigational agonist antibody targeting CD137, also known as 4-1BB.